AI Article Synopsis
- * A 59-year-old man with metastatic colorectal cancer showed a significant response to a new treatment combining fruquintinib and toripalimab after failing multiple chemotherapy lines. * The patient, who previously underwent surgeries for rectal cancer and liver metastasis, achieved partial response within 3 months and a complete response in lung masses within a year. * This combination treatment resulted in over 17 months of progression-free survival, suggesting it may enhance the prognosis for patients with metastatic colorectal cancer.
Article Abstract
The options for treating metastatic colorectal cancer are limited after failure of second-line chemotherapy. In this case report, we present the outcome of a 59-year-old male patient who underwent radical resection for rectal cancer in November 2018 and hepatectomy for liver metastasis in January 2021. His metastatic rectal cancer presented a remarkable response to the combination of fruquintinib and toripalimab after the failure of multiline chemotherapies. The patient achieved partial response within 3 months and clinical complete response of pulmonary masses within 12 months. As of now, the patient maintains a good quality of life, and the progression-free survival has been more than 17 months. In conclusion, the combination of fruquintinib and PD-1 inhibitors can improve the prognosis of metastatic colorectal cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2023-0235 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!